Article Text


OP0086 The fully human anti-tnf monoclonal antibody, adalimumab (d2e7), dose ranging study: the 24-week clinical results in patients with active ra on methotrexate therapy (the armada trial)
  1. E Keystone1,
  2. ME Weinblatt2,
  3. M Weisman3,
  4. D Furst4,
  5. H Paulus3,
  6. C Birbara5,
  7. S Fischkoff6,
  8. EK Chartash6
  1. 1Ctr for Advanced Therapeutics, Mt Sinai Hosp, Toronto, Canada
  2. 2Division of Rheumatology, Brigham and Womens Hospital, Boston
  3. 3Division of Rheumatology, UCLA, Los Angeles
  4. 4Division of Rheumatology, Virginia Mason Clinic, Seattle
  5. 5Division of Rheumatology, Univ of Mass, Worcester
  6. 6Department of Immunology, Knoll Pharmaceutical Co., Mt. Olive, USA


Objectives To investigate the clinical efficacy and safety of adalimumab (D2E7), given subcutaneously in combination with methotrexate (MTX) to rheumatoid arthritis (RA) patients who are partial responders to MTX treatment.

Methods The ARMADA Trial was a double-blind placebo controlled study of 271 patients who had active RA despite concurrent stable doses of MTX. The patients were randomised to receive placebo or the fully human anti TNF monoclonal antibody, adalimumab (D2E7), at one of 3 doses (20, 40 and 80 mg every other week). Baseline demographic characteristics included: 76.8% females, 81% rheumatoid factor positivity, mean age 55.5 years, mean duration of RA 12.3 years, mean dose of MTX 16.8 mg/week, mean number of previous DMARDs 3.0. These characteristics were well matched between treatment groups.

Results Clinical efficacy results for the placebo controlled 24-week period are displayed in the Table 1 below. Adverse events in the adalimumab (D2E7) groups are similar to placebo. Only injection site reactions occurred more frequently with adalimumab (D2E7) in 14.8% of the patients versus 3.2% in the placebo group.

Abstract OP0086 Table 1

Conclusion The efficacy of the fully human anti-TNFα monoclonal antibody, adalimumab (D2E7), in addition to MTX in patients with longstanding RA is significantly better than placebo when given every other week subcutaneously. The ACR50 and ACR70 responses were impressive in this group of patients with refractory RA.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.